Global Phage Therapy

Phage Therapy Comprehensive Study by Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), Route of Administration (Oral, Topical), Targeted Bacteria (Escherichia coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella, Others), Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Cystic Fibrosis, Others) Players and Region - Global Market Outlook to 2027

Phage Therapy Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Phage therapy is another name for bacteriophage therapy. For the treatment of bacterial illnesses, viruses are required. Bacteriophages or phages are bacterial viruses. Phages are bacteria-fighting viruses that are harmless to animals, plants, and humans. Bacteriophages are thought to be bacteria's natural enemies. Bacteriophages can be found in soil, water, sewage, and other environments where bacteria are present. Antibiotic phage therapy is gaining popularity as a treatment option. As a result, phage treatment is defined as the therapeutic use of lytic bacteriophages to treat pathogenic bacterial illnesses. Phage Therapy is highly particular to the bacteria it is used to kill. Because bacteriophages do not directly influence human cells, their use is tailored at a single bacterial species, minimizing off-target effects on the microbiome or human patient. Because of the rising occurrence of drug-resistant diseases, increased research, and product development, the Phage Therapy market is booming. The high cost of phage therapy and a scarcity of experienced experts, on the other hand, are likely to stifle the worldwide bacteriophage therapy market's expansion.
This growth is primarily driven by Increase in Prevalence of Foodborne Diseases and Growing Research and Development Activities.

Globally, a noticeable market trend is evident Increasing Prevalence of Antibiotic-Resistant Infections. Major Players, such as Locus Biosciences (United States), Armata Pharmaceuticals(United States), Micreos BV (Netherlands), Pherecydes Pharma (France), Intralytix, Inc(United States), Phagelux, Inc (China), Nextbiotics(United States), TechnoPhage (Portugal), Eligo Bioscience SA (France) and Phagomed Biopharma GmbH (Austria) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

February 2021 – Locus Biosciences completes a first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy.

Market Drivers
  • Increase in Prevalence of Foodborne Diseases
  • Growing Research and Development Activities

Market Trend
  • Increasing Prevalence of Antibiotic-Resistant Infections

Restraints
  • Stringent Regulatory Factors

Opportunities
Adoption of Inorganic Growth Strategies by Major Key Players and Growth Opportunities in Untapped Market
Challenges
Presence of alternative treatment and High Cost of Therapy

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Phage Therapy Study Sheds Light on
— The Phage Therapy Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Phage Therapy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Phage Therapy industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Diagnostic
  • Antimicrobial Drug Discovery
  • Veterinary Medicines
  • Others
By Route of Administration
  • Oral
  • Topical

By Targeted Bacteria
  • Escherichia coli
  • Staphylococcus Aureus
  • Streptococcus
  • Pseudomonas Aeruginosa
  • Salmonella
  • Others

By Disease Indication
  • Urinary Tract Infections
  • Chronic Otitis
  • Dental Extraction
  • Chronic Ulcerative Colitis
  • Cystic Fibrosis
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Prevalence of Foodborne Diseases
      • 3.2.2. Growing Research and Development Activities
    • 3.3. Market Challenges
      • 3.3.1. Presence of alternative treatment
      • 3.3.2. High Cost of Therapy
    • 3.4. Market Trends
      • 3.4.1. Increasing Prevalence of Antibiotic-Resistant Infections
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Phage Therapy, by Application, Route of Administration, Targeted Bacteria, Disease Indication and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Phage Therapy (Value)
      • 5.2.1. Global Phage Therapy by: Application (Value)
        • 5.2.1.1. Diagnostic
        • 5.2.1.2. Antimicrobial Drug Discovery
        • 5.2.1.3. Veterinary Medicines
        • 5.2.1.4. Others
      • 5.2.2. Global Phage Therapy by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Topical
      • 5.2.3. Global Phage Therapy by: Targeted Bacteria (Value)
        • 5.2.3.1. Escherichia coli
        • 5.2.3.2. Staphylococcus Aureus
        • 5.2.3.3. Streptococcus
        • 5.2.3.4. Pseudomonas Aeruginosa
        • 5.2.3.5. Salmonella
        • 5.2.3.6. Others
      • 5.2.4. Global Phage Therapy by: Disease Indication (Value)
        • 5.2.4.1. Urinary Tract Infections
        • 5.2.4.2. Chronic Otitis
        • 5.2.4.3. Dental Extraction
        • 5.2.4.4. Chronic Ulcerative Colitis
        • 5.2.4.5. Cystic Fibrosis
        • 5.2.4.6. Others
      • 5.2.5. Global Phage Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Phage Therapy (Price)
  • 6. Phage Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Locus Biosciences (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Armata Pharmaceuticals(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Micreos BV (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pherecydes Pharma (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Intralytix, Inc(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Phagelux, Inc (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nextbiotics(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. TechnoPhage (Portugal)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eligo Bioscience SA (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Phagomed Biopharma GmbH (Austria)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Phage Therapy Sale, by Application, Route of Administration, Targeted Bacteria, Disease Indication and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Phage Therapy (Value)
      • 7.2.1. Global Phage Therapy by: Application (Value)
        • 7.2.1.1. Diagnostic
        • 7.2.1.2. Antimicrobial Drug Discovery
        • 7.2.1.3. Veterinary Medicines
        • 7.2.1.4. Others
      • 7.2.2. Global Phage Therapy by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Topical
      • 7.2.3. Global Phage Therapy by: Targeted Bacteria (Value)
        • 7.2.3.1. Escherichia coli
        • 7.2.3.2. Staphylococcus Aureus
        • 7.2.3.3. Streptococcus
        • 7.2.3.4. Pseudomonas Aeruginosa
        • 7.2.3.5. Salmonella
        • 7.2.3.6. Others
      • 7.2.4. Global Phage Therapy by: Disease Indication (Value)
        • 7.2.4.1. Urinary Tract Infections
        • 7.2.4.2. Chronic Otitis
        • 7.2.4.3. Dental Extraction
        • 7.2.4.4. Chronic Ulcerative Colitis
        • 7.2.4.5. Cystic Fibrosis
        • 7.2.4.6. Others
      • 7.2.5. Global Phage Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Phage Therapy (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Phage Therapy: by Application(USD Million)
  • Table 2. Phage Therapy Diagnostic , by Region USD Million (2016-2021)
  • Table 3. Phage Therapy Antimicrobial Drug Discovery , by Region USD Million (2016-2021)
  • Table 4. Phage Therapy Veterinary Medicines , by Region USD Million (2016-2021)
  • Table 5. Phage Therapy Others , by Region USD Million (2016-2021)
  • Table 6. Phage Therapy: by Route of Administration(USD Million)
  • Table 7. Phage Therapy Oral , by Region USD Million (2016-2021)
  • Table 8. Phage Therapy Topical , by Region USD Million (2016-2021)
  • Table 9. Phage Therapy: by Targeted Bacteria(USD Million)
  • Table 10. Phage Therapy Escherichia coli , by Region USD Million (2016-2021)
  • Table 11. Phage Therapy Staphylococcus Aureus , by Region USD Million (2016-2021)
  • Table 12. Phage Therapy Streptococcus , by Region USD Million (2016-2021)
  • Table 13. Phage Therapy Pseudomonas Aeruginosa , by Region USD Million (2016-2021)
  • Table 14. Phage Therapy Salmonella , by Region USD Million (2016-2021)
  • Table 15. Phage Therapy Others , by Region USD Million (2016-2021)
  • Table 16. Phage Therapy: by Disease Indication(USD Million)
  • Table 17. Phage Therapy Urinary Tract Infections , by Region USD Million (2016-2021)
  • Table 18. Phage Therapy Chronic Otitis , by Region USD Million (2016-2021)
  • Table 19. Phage Therapy Dental Extraction , by Region USD Million (2016-2021)
  • Table 20. Phage Therapy Chronic Ulcerative Colitis , by Region USD Million (2016-2021)
  • Table 21. Phage Therapy Cystic Fibrosis , by Region USD Million (2016-2021)
  • Table 22. Phage Therapy Others , by Region USD Million (2016-2021)
  • Table 23. South America Phage Therapy, by Country USD Million (2016-2021)
  • Table 24. South America Phage Therapy, by Application USD Million (2016-2021)
  • Table 25. South America Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 26. South America Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 27. South America Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 28. Brazil Phage Therapy, by Application USD Million (2016-2021)
  • Table 29. Brazil Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 30. Brazil Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 31. Brazil Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 32. Argentina Phage Therapy, by Application USD Million (2016-2021)
  • Table 33. Argentina Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 34. Argentina Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 35. Argentina Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 36. Rest of South America Phage Therapy, by Application USD Million (2016-2021)
  • Table 37. Rest of South America Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 38. Rest of South America Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 39. Rest of South America Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 40. Asia Pacific Phage Therapy, by Country USD Million (2016-2021)
  • Table 41. Asia Pacific Phage Therapy, by Application USD Million (2016-2021)
  • Table 42. Asia Pacific Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 43. Asia Pacific Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 44. Asia Pacific Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 45. China Phage Therapy, by Application USD Million (2016-2021)
  • Table 46. China Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 47. China Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 48. China Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 49. Japan Phage Therapy, by Application USD Million (2016-2021)
  • Table 50. Japan Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 51. Japan Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 52. Japan Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 53. India Phage Therapy, by Application USD Million (2016-2021)
  • Table 54. India Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 55. India Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 56. India Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 57. South Korea Phage Therapy, by Application USD Million (2016-2021)
  • Table 58. South Korea Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 59. South Korea Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 60. South Korea Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 61. Taiwan Phage Therapy, by Application USD Million (2016-2021)
  • Table 62. Taiwan Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 63. Taiwan Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 64. Taiwan Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 65. Australia Phage Therapy, by Application USD Million (2016-2021)
  • Table 66. Australia Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 67. Australia Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 68. Australia Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Phage Therapy, by Application USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 71. Rest of Asia-Pacific Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 72. Rest of Asia-Pacific Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 73. Europe Phage Therapy, by Country USD Million (2016-2021)
  • Table 74. Europe Phage Therapy, by Application USD Million (2016-2021)
  • Table 75. Europe Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 76. Europe Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 77. Europe Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 78. Germany Phage Therapy, by Application USD Million (2016-2021)
  • Table 79. Germany Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 80. Germany Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 81. Germany Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 82. France Phage Therapy, by Application USD Million (2016-2021)
  • Table 83. France Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 84. France Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 85. France Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 86. Italy Phage Therapy, by Application USD Million (2016-2021)
  • Table 87. Italy Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 88. Italy Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 89. Italy Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 90. United Kingdom Phage Therapy, by Application USD Million (2016-2021)
  • Table 91. United Kingdom Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 92. United Kingdom Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 93. United Kingdom Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 94. Netherlands Phage Therapy, by Application USD Million (2016-2021)
  • Table 95. Netherlands Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 96. Netherlands Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 97. Netherlands Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 98. Rest of Europe Phage Therapy, by Application USD Million (2016-2021)
  • Table 99. Rest of Europe Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 100. Rest of Europe Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 101. Rest of Europe Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 102. MEA Phage Therapy, by Country USD Million (2016-2021)
  • Table 103. MEA Phage Therapy, by Application USD Million (2016-2021)
  • Table 104. MEA Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 105. MEA Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 106. MEA Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 107. Middle East Phage Therapy, by Application USD Million (2016-2021)
  • Table 108. Middle East Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 109. Middle East Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 110. Middle East Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 111. Africa Phage Therapy, by Application USD Million (2016-2021)
  • Table 112. Africa Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 113. Africa Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 114. Africa Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 115. North America Phage Therapy, by Country USD Million (2016-2021)
  • Table 116. North America Phage Therapy, by Application USD Million (2016-2021)
  • Table 117. North America Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 118. North America Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 119. North America Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 120. United States Phage Therapy, by Application USD Million (2016-2021)
  • Table 121. United States Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 122. United States Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 123. United States Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 124. Canada Phage Therapy, by Application USD Million (2016-2021)
  • Table 125. Canada Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 126. Canada Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 127. Canada Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 128. Mexico Phage Therapy, by Application USD Million (2016-2021)
  • Table 129. Mexico Phage Therapy, by Route of Administration USD Million (2016-2021)
  • Table 130. Mexico Phage Therapy, by Targeted Bacteria USD Million (2016-2021)
  • Table 131. Mexico Phage Therapy, by Disease Indication USD Million (2016-2021)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Phage Therapy: by Application(USD Million)
  • Table 143. Phage Therapy Diagnostic , by Region USD Million (2022-2027)
  • Table 144. Phage Therapy Antimicrobial Drug Discovery , by Region USD Million (2022-2027)
  • Table 145. Phage Therapy Veterinary Medicines , by Region USD Million (2022-2027)
  • Table 146. Phage Therapy Others , by Region USD Million (2022-2027)
  • Table 147. Phage Therapy: by Route of Administration(USD Million)
  • Table 148. Phage Therapy Oral , by Region USD Million (2022-2027)
  • Table 149. Phage Therapy Topical , by Region USD Million (2022-2027)
  • Table 150. Phage Therapy: by Targeted Bacteria(USD Million)
  • Table 151. Phage Therapy Escherichia coli , by Region USD Million (2022-2027)
  • Table 152. Phage Therapy Staphylococcus Aureus , by Region USD Million (2022-2027)
  • Table 153. Phage Therapy Streptococcus , by Region USD Million (2022-2027)
  • Table 154. Phage Therapy Pseudomonas Aeruginosa , by Region USD Million (2022-2027)
  • Table 155. Phage Therapy Salmonella , by Region USD Million (2022-2027)
  • Table 156. Phage Therapy Others , by Region USD Million (2022-2027)
  • Table 157. Phage Therapy: by Disease Indication(USD Million)
  • Table 158. Phage Therapy Urinary Tract Infections , by Region USD Million (2022-2027)
  • Table 159. Phage Therapy Chronic Otitis , by Region USD Million (2022-2027)
  • Table 160. Phage Therapy Dental Extraction , by Region USD Million (2022-2027)
  • Table 161. Phage Therapy Chronic Ulcerative Colitis , by Region USD Million (2022-2027)
  • Table 162. Phage Therapy Cystic Fibrosis , by Region USD Million (2022-2027)
  • Table 163. Phage Therapy Others , by Region USD Million (2022-2027)
  • Table 164. South America Phage Therapy, by Country USD Million (2022-2027)
  • Table 165. South America Phage Therapy, by Application USD Million (2022-2027)
  • Table 166. South America Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 167. South America Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 168. South America Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 169. Brazil Phage Therapy, by Application USD Million (2022-2027)
  • Table 170. Brazil Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 171. Brazil Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 172. Brazil Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 173. Argentina Phage Therapy, by Application USD Million (2022-2027)
  • Table 174. Argentina Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 175. Argentina Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 176. Argentina Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 177. Rest of South America Phage Therapy, by Application USD Million (2022-2027)
  • Table 178. Rest of South America Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 179. Rest of South America Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 180. Rest of South America Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 181. Asia Pacific Phage Therapy, by Country USD Million (2022-2027)
  • Table 182. Asia Pacific Phage Therapy, by Application USD Million (2022-2027)
  • Table 183. Asia Pacific Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 184. Asia Pacific Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 185. Asia Pacific Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 186. China Phage Therapy, by Application USD Million (2022-2027)
  • Table 187. China Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 188. China Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 189. China Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 190. Japan Phage Therapy, by Application USD Million (2022-2027)
  • Table 191. Japan Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 192. Japan Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 193. Japan Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 194. India Phage Therapy, by Application USD Million (2022-2027)
  • Table 195. India Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 196. India Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 197. India Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 198. South Korea Phage Therapy, by Application USD Million (2022-2027)
  • Table 199. South Korea Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 200. South Korea Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 201. South Korea Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 202. Taiwan Phage Therapy, by Application USD Million (2022-2027)
  • Table 203. Taiwan Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 204. Taiwan Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 205. Taiwan Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 206. Australia Phage Therapy, by Application USD Million (2022-2027)
  • Table 207. Australia Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 208. Australia Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 209. Australia Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 210. Rest of Asia-Pacific Phage Therapy, by Application USD Million (2022-2027)
  • Table 211. Rest of Asia-Pacific Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 212. Rest of Asia-Pacific Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 213. Rest of Asia-Pacific Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 214. Europe Phage Therapy, by Country USD Million (2022-2027)
  • Table 215. Europe Phage Therapy, by Application USD Million (2022-2027)
  • Table 216. Europe Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 217. Europe Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 218. Europe Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 219. Germany Phage Therapy, by Application USD Million (2022-2027)
  • Table 220. Germany Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 221. Germany Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 222. Germany Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 223. France Phage Therapy, by Application USD Million (2022-2027)
  • Table 224. France Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 225. France Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 226. France Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 227. Italy Phage Therapy, by Application USD Million (2022-2027)
  • Table 228. Italy Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 229. Italy Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 230. Italy Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 231. United Kingdom Phage Therapy, by Application USD Million (2022-2027)
  • Table 232. United Kingdom Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 233. United Kingdom Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 234. United Kingdom Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 235. Netherlands Phage Therapy, by Application USD Million (2022-2027)
  • Table 236. Netherlands Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 237. Netherlands Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 238. Netherlands Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 239. Rest of Europe Phage Therapy, by Application USD Million (2022-2027)
  • Table 240. Rest of Europe Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 241. Rest of Europe Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 242. Rest of Europe Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 243. MEA Phage Therapy, by Country USD Million (2022-2027)
  • Table 244. MEA Phage Therapy, by Application USD Million (2022-2027)
  • Table 245. MEA Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 246. MEA Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 247. MEA Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 248. Middle East Phage Therapy, by Application USD Million (2022-2027)
  • Table 249. Middle East Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 250. Middle East Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 251. Middle East Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 252. Africa Phage Therapy, by Application USD Million (2022-2027)
  • Table 253. Africa Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 254. Africa Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 255. Africa Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 256. North America Phage Therapy, by Country USD Million (2022-2027)
  • Table 257. North America Phage Therapy, by Application USD Million (2022-2027)
  • Table 258. North America Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 259. North America Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 260. North America Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 261. United States Phage Therapy, by Application USD Million (2022-2027)
  • Table 262. United States Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 263. United States Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 264. United States Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 265. Canada Phage Therapy, by Application USD Million (2022-2027)
  • Table 266. Canada Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 267. Canada Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 268. Canada Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 269. Mexico Phage Therapy, by Application USD Million (2022-2027)
  • Table 270. Mexico Phage Therapy, by Route of Administration USD Million (2022-2027)
  • Table 271. Mexico Phage Therapy, by Targeted Bacteria USD Million (2022-2027)
  • Table 272. Mexico Phage Therapy, by Disease Indication USD Million (2022-2027)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Phage Therapy: by Application USD Million (2016-2021)
  • Figure 5. Global Phage Therapy: by Route of Administration USD Million (2016-2021)
  • Figure 6. Global Phage Therapy: by Targeted Bacteria USD Million (2016-2021)
  • Figure 7. Global Phage Therapy: by Disease Indication USD Million (2016-2021)
  • Figure 8. South America Phage Therapy Share (%), by Country
  • Figure 9. Asia Pacific Phage Therapy Share (%), by Country
  • Figure 10. Europe Phage Therapy Share (%), by Country
  • Figure 11. MEA Phage Therapy Share (%), by Country
  • Figure 12. North America Phage Therapy Share (%), by Country
  • Figure 13. Global Phage Therapy share by Players 2021 (%)
  • Figure 14. Global Phage Therapy share by Players (Top 3) 2021(%)
  • Figure 15. Global Phage Therapy share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Locus Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 18. Locus Biosciences (United States) Revenue: by Geography 2021
  • Figure 19. Armata Pharmaceuticals(United States) Revenue, Net Income and Gross profit
  • Figure 20. Armata Pharmaceuticals(United States) Revenue: by Geography 2021
  • Figure 21. Micreos BV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 22. Micreos BV (Netherlands) Revenue: by Geography 2021
  • Figure 23. Pherecydes Pharma (France) Revenue, Net Income and Gross profit
  • Figure 24. Pherecydes Pharma (France) Revenue: by Geography 2021
  • Figure 25. Intralytix, Inc(United States) Revenue, Net Income and Gross profit
  • Figure 26. Intralytix, Inc(United States) Revenue: by Geography 2021
  • Figure 27. Phagelux, Inc (China) Revenue, Net Income and Gross profit
  • Figure 28. Phagelux, Inc (China) Revenue: by Geography 2021
  • Figure 29. Nextbiotics(United States) Revenue, Net Income and Gross profit
  • Figure 30. Nextbiotics(United States) Revenue: by Geography 2021
  • Figure 31. TechnoPhage (Portugal) Revenue, Net Income and Gross profit
  • Figure 32. TechnoPhage (Portugal) Revenue: by Geography 2021
  • Figure 33. Eligo Bioscience SA (France) Revenue, Net Income and Gross profit
  • Figure 34. Eligo Bioscience SA (France) Revenue: by Geography 2021
  • Figure 35. Phagomed Biopharma GmbH (Austria) Revenue, Net Income and Gross profit
  • Figure 36. Phagomed Biopharma GmbH (Austria) Revenue: by Geography 2021
  • Figure 37. Global Phage Therapy: by Application USD Million (2022-2027)
  • Figure 38. Global Phage Therapy: by Route of Administration USD Million (2022-2027)
  • Figure 39. Global Phage Therapy: by Targeted Bacteria USD Million (2022-2027)
  • Figure 40. Global Phage Therapy: by Disease Indication USD Million (2022-2027)
  • Figure 41. South America Phage Therapy Share (%), by Country
  • Figure 42. Asia Pacific Phage Therapy Share (%), by Country
  • Figure 43. Europe Phage Therapy Share (%), by Country
  • Figure 44. MEA Phage Therapy Share (%), by Country
  • Figure 45. North America Phage Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Locus Biosciences (United States)
  • Armata Pharmaceuticals(United States)
  • Micreos BV (Netherlands)
  • Pherecydes Pharma (France)
  • Intralytix, Inc(United States)
  • Phagelux, Inc (China)
  • Nextbiotics(United States)
  • TechnoPhage (Portugal)
  • Eligo Bioscience SA (France)
  • Phagomed Biopharma GmbH (Austria)
Additional players considered in the study are as follows:
Phi Therapeutics(United States) , Fixed-phage Ltd (United Kingdom) , Eliava Biopreparations (Georgia)
Select User Access Type

Key Highlights of Report


Mar 2022 249 Pages 52 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Phage Therapy Quantitative research analysis
Global Phage Therapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Phage Therapy market is expected to see a CAGR of % during projected year 2021 to 2027.
Top performing companies in the Global Phage Therapy market are Locus Biosciences (United States), Armata Pharmaceuticals(United States), Micreos BV (Netherlands), Pherecydes Pharma (France), Intralytix, Inc(United States), Phagelux, Inc (China), Nextbiotics(United States), TechnoPhage (Portugal), Eligo Bioscience SA (France) and Phagomed Biopharma GmbH (Austria), to name a few.
is dominating the Phage Therapy Market.

Know More About Global Phage Therapy Report?

Have a Query? Click Here

Other Related Reports

Respiratory Virus Infection Drugs Comprehensive Study by Type (Penicillin VK, Amoxicillin, Penicillin G benzathine, Cefadroxil, Erythromycin, Amoxicillin and clavulanate, Others), Disease Type (COVID...
$ 3750
Behcet's Disease Treatment Comprehensive Study by Type (Anti-inflammatory Medications (Ibuprofen), Topical Ointments (Corticosteroid), Immunosuppressive Medications), Route of Administration (Oral, I...
$ 3750
Wolff Parkinson White Syndrome Treatment Comprehensive Study by Type (Type A, Type B), Treatment (Drugs {Anti-Arrhythmic, Beta-Blockers, Others}, Cardioversion, Radiofrequency Catheter Ablation, Surg...
$ 3750
Transurethral Resection of the Prostate (TURP) Comprehensive Study by Application (Hospital, Clinic, Laboratory), Devices (Resectoscopes, Catheters and Resectoscopes Electrodes, Monopolar Electrodes...
$ 3650
Amifostine Market Comprehensive Study by Application (Ovarian Cancer Adjuvant Therapy, Head and Neck Cancer Adjuvant Therapy, Others), Distribution Channel (Online, Offline), Type of Drug (Tablet, Ca...
$ 3450
Hormone Refractory Breast Cancer Comprehensive Study by Treatment (Hormone receptor-based therapy, Tumor markers therapy, Gene expression therapy, Gene mutation therapy), End-users (Hospitals, Clinic...
$ 3450